LSE:HLN NYSE:HLN

Haleon PLC

Market:

LSE

Price

369.20 GBX

Day Change

-0.38%

Market Cap:

£32.48 b

52 weeks high

416.10

52 weeks low

274.40

Filter by article type

Viewing results 1-25 of 43

What Brokers Say

Haleon performance might be stronger than you think, analyst repeats 'buy' rating

on 5/5/26

What Brokers Say

Haleon set for slow start from weak flu season, with Middle East cushion

on 30/3/26

What Brokers Say

Haleon's weaker sales make mid-term targets 'not look credible'

on 26/2/26

What Brokers Say

Haleon hit by channel shift concerns

on 22/1/26

What Brokers Say

Will Haleon deliver solid margin growth despite weaker cold season?

on 21/1/26

What Brokers Say

Haleon not out of the woods yet, with analysts saying questions still remain

on 30/10/25

What Brokers Say

Are Haleon's headaches set to ease? Here's one leading bank's take

on 9/10/25

What Brokers Say

Haleon tops FTSE 100 fallers after downgrade

on 16/9/25

What Brokers Say

Haleon’s resilience and brand power shine through in Q2

on 1/8/25

What Brokers Say

Kenvue takeover speculation heats up ahead of M&A window

on 16/6/25

What Brokers Say

Haleon figures meet expectations; but analysts and investors wanted more

on 27/2/25

What Brokers Say

Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%

on 27/2/25

What Brokers Say

Haleon results could provide tonic for investor anxiety, says Barclays

on 25/2/25

What Brokers Say

Haleon gets target hike as UBS raises 'forever' sales target

on 9/10/24

What Brokers Say

Haleon’s buy rating restated after Pfizer cuts down stake

on 1/10/24

What Brokers Say

Haleon a rare riser on tough day as Deutsche Bank hails resilience

on 2/8/24

What Brokers Say

Futura: Plenty of catalysts over the next few months, says broker

on 20/6/24

What Brokers Say

Rolls-Royce, ASML, Flutter, Beazley tipped among 'whatever weather winners'

on 10/4/24

What Brokers Say

Haleon overhang can be gone in a year, suggests Barclays

on 4/4/24

What Brokers Say

Haleon building 'solid track record' says Barclays

on 4/3/24

What Brokers Say

Haleon needs to calm consumer goods sector after Reckitt shock

on 28/2/24

Spin-outs on the rise as companies try to win out in desolate M&A market

on 4/10/23

Futura Medical CEO James Barder discusses FDA approval, market share gains, and plans for Eroxon

on 22/9/23

What Brokers Say

Haleon an ‘excellent choice’ for Futura’s US ambitions, says broker

on 17/7/23

What Brokers Say

British household names looking 'cheap' after poor six months

on 10/7/23